Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - The stock of Wens Foodstuff Group Co., Ltd. has shown a positive trend with a 14.23% increase year-to-date, despite a slight decline in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 758.17 billion yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 52.56 billion yuan [2]. - Cumulatively, the company has distributed 301.10 billion yuan in dividends since its A-share listing, with 69.35 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wens was 81,100, a decrease of 10.94% from the previous period. The average number of tradable shares per shareholder increased by 12.11% to 73,543 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 144 million shares, an increase of 5.50 million shares compared to the previous period. Conversely, E Fund's ChiNext ETF reduced its holdings by 19.09 million shares to 113 million shares [3]. Stock Market Activity - On November 10, Wens' stock price rose by 2.01% to 18.29 yuan per share, with a trading volume of 724 million yuan and a turnover rate of 0.67%. The total market capitalization reached 121.7 billion yuan [1]. - The net inflow of main funds was 32.71 million yuan, with significant buying and selling activities recorded [1].

Core Viewpoint - Kanghua Biotech's stock has shown significant growth this year, with a 51.82% increase, despite a decline in revenue and net profit for the first nine months of 2025 [1][2]. Group 1: Stock Performance - On November 7, Kanghua Biotech's stock rose by 2.01%, reaching 81.29 CNY per share, with a trading volume of 2.09 billion CNY and a turnover rate of 2.21% [1]. - The company's market capitalization stands at 10.563 billion CNY [1]. - Year-to-date, the stock has increased by 51.82%, with a 5.24% rise over the last five trading days, 5.57% over the last 20 days, and 4.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Kanghua Biotech reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2]. - The company has distributed a total of 686 million CNY in dividends since its A-share listing, with 462 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 18,300, a rise of 6.13%, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 1.1826 million shares, marking its entry as a new shareholder [3]. - The Southern CSI 1000 ETF is the seventh largest shareholder with 850,600 shares, having decreased its holdings by 11,000 shares compared to the previous period [3].

Core Viewpoint - TianKang Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Group 1: Stock Performance - On November 7, TianKang Biological's stock rose by 2.03%, reaching 7.53 CNY per share, with a trading volume of 80.02 million CNY and a turnover rate of 0.79% [1]. - The stock has increased by 18.96% year-to-date, with a 2.03% rise in the last five trading days, a 2.46% decline over the last 20 days, and a 16.74% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, TianKang Biological reported a revenue of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2]. - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Business Overview - TianKang Biological, established on December 28, 2000, and listed on December 26, 2006, is based in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [1]. - The revenue composition of the company includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Group 4: Shareholder Information - As of October 31, the number of shareholders for TianKang Biological was 58,000, a decrease of 3.11% from the previous period, with an average of 23,548 circulating shares per shareholder, an increase of 3.21% [2]. - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth-largest shareholder with 24.30 million shares, and Hong Kong Central Clearing Limited as the seventh-largest shareholder with 15.03 million shares, marking a new entry [3].

Core Viewpoint - Tianbang Food's stock has experienced a decline in recent trading sessions, with a notable drop in both revenue and net profit year-on-year, indicating potential challenges in the company's financial performance [1][2]. Group 1: Stock Performance - On November 7, Tianbang Food's stock fell by 2.07%, trading at 2.84 CNY per share, with a total market capitalization of 6.31 billion CNY [1]. - The stock has increased by 1.79% year-to-date, but has seen declines of 1.39% over the last five trading days, 2.07% over the last twenty days, and 7.19% over the last sixty days [1]. - The company has appeared on the trading leaderboard once this year, with a net buy of 20.53 million CNY on May 8 [1]. Group 2: Financial Performance - For the period from January to September 2025, Tianbang Food reported a revenue of 6.72 billion CNY, a year-on-year decrease of 5.98%, and a net profit attributable to shareholders of 260 million CNY, down 80.65% year-on-year [2]. - The company has distributed a total of 1.185 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [2]. Group 3: Business Overview - Tianbang Food, established on September 25, 1996, and listed on April 3, 2007, is primarily engaged in pig farming and pork product processing, with revenue contributions of 63.82% from pig farming, 33.25% from food processing, 2.85% from feed products, and 0.08% from other sources [1]. - The company operates within the agricultural sector, specifically in the pig farming industry, and is associated with various concepts including the metaverse, pork, prepared dishes, animal vaccines, and avian influenza medications [2].

Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]

Core Viewpoint - TianKang Biological experienced a stock price increase of 2.03% on November 3, reaching 7.53 CNY per share, with a total market capitalization of 10.28 billion CNY [1] Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006 [1] - The company specializes in the production and sales of biological vaccines for livestock and poultry, feed, plant protein, breeding of breeding pigs, pig farming, slaughter processing, and meat product sales [1] - The revenue composition includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1] Financial Performance - For the period from January to September 2025, TianKang Biological achieved an operating income of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2] - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed over the past three years [3] Shareholder Information - As of October 20, 2025, the number of shareholders decreased by 1.20% to 59,800, while the average number of circulating shares per person increased by 1.21% to 22,815 shares [2] - Notable institutional holdings include: Guotai Zhongzheng Livestock Breeding ETF as the fifth largest shareholder with 24.30 million shares, an increase of 8.75 million shares; Hong Kong Central Clearing Limited as the seventh largest shareholder with 15.03 million shares, a new entry; and Jiashi Agricultural Industry Stock A as the eighth largest shareholder with 13.91 million shares, an increase of 3.61 million shares [3]

Core Viewpoint - Shenyuan Biological is a leading enterprise in the field of veterinary synthetic peptide vaccines in China, with a focus on research, production, and sales of veterinary biological products [1] Group 1: Business Performance - In Q3 2025, Shenyuan Biological reported revenue of 238 million yuan, ranking 10th in the industry, significantly lower than the top company, Zhongmu Co., which had 4.442 billion yuan, and the second, Ruipu Biological, with 2.544 billion yuan [2] - The net profit for the same period was -3.0229 million yuan, placing the company 12th in the industry, far behind Ruipu Biological's 391 million yuan and KQ Biological's 337 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenyuan Biological's debt-to-asset ratio was 8.94%, an increase from 6.72% year-on-year, but still below the industry average of 28.36% [3] - The gross profit margin for Q3 2025 was 59.49%, down from 61.12% year-on-year, yet higher than the industry average of 40.13% [3] Group 3: Executive Compensation - The chairman, Nie Dongsheng, received a salary of 1.1286 million yuan in 2024, a decrease of 49,000 yuan from 2023 [4] - The general manager, Zhang Zhen, had a salary of 990,000 yuan in 2024, an increase of 46,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 30.87% to 12,400, while the average number of circulating A-shares held per account decreased by 23.59% to 33,100 [5]

Core Viewpoint - Jinhe Biology is a significant player in the animal health products industry, focusing on the production, sales, research, and services of animal health products, with strong technical capabilities and market competitiveness in the veterinary pharmaceutical sector [1] Group 1: Business Performance - In Q3 2025, Jinhe Biology achieved a revenue of 2.036 billion yuan, ranking third among 14 companies in the industry, surpassing the industry average of 1.067 billion yuan and the median of 780 million yuan, but below the top two companies, Zhongmu Co. at 4.442 billion yuan and Ruipu Biology at 2.544 billion yuan [2] - The main business composition includes veterinary chemical drugs at 860 million yuan (61.83%), starch and related products at 275 million yuan (19.76%), veterinary vaccines at 155 million yuan (11.12%), environmental services at 69.13 million yuan (4.97%), and other products at 29.92 million yuan (2.15%) [2] - The net profit for the same period was 135 million yuan, ranking seventh in the industry, above the average of 115 million yuan and the median of 87.64 million yuan, but below the top two companies, Ruipu Biology at 391 million yuan and KQ Biology at 337 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jinhe Biology's debt-to-asset ratio was 53.45%, a decrease from 56.30% in the previous year but higher than the industry average of 28.36%, indicating relatively high debt pressure [3] - The gross profit margin for Q3 2025 was 33.83%, slightly up from 33.27% year-on-year but below the industry average of 40.13%, suggesting room for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 21.69% to 50,500, while the average number of circulating A-shares held per shareholder increased by 28.11% to 14,800 [5] - Among the top ten circulating shareholders, Guotai Junan CSI Livestock Breeding ETF ranked third with 12.0555 million shares, an increase of 4.3964 million shares from the previous period [5] Group 4: Future Outlook - Pacific Securities noted significant growth in Jinhe Biology's revenue and net profit in the first half of 2025, with notable revenue growth in the veterinary pharmaceutical sector driven by the domestic and international market for its main product, Jinmeisu Premix, alongside cost reductions [5] - The company is expected to achieve revenues of 2.89 billion, 3.41 billion, and 3.92 billion yuan, with net profits of 246 million, 314 million, and 331 million yuan from 2025 to 2027, maintaining a "buy" rating [5] - Huaxi Securities also highlighted strong performance in the first half of 2025, with growth in both volume and price in the chemical drug sector, increased domestic market promotion, and robust overseas demand [6]

Core Viewpoint - TianKang Biological is a leading domestic supplier of biological vaccines and feed for livestock and poultry, with significant investment value due to its full industry chain advantages [1] Group 1: Business Performance - In Q3 2025, TianKang Biological achieved operating revenue of 13.61 billion, ranking 4th among 10 companies in the industry, with the top company, HeFeng Co., at 28.07 billion [2] - The net profit for the same period was 505 million, ranking 1st in the industry, with the second being AoNong Biological at 439 million [2] - The revenue composition includes 2.85 billion from the pig breeding industry chain, accounting for 32.20%, and 2.43 billion from feed, accounting for 27.51% [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio was 47.86%, lower than the previous year's 49.89% and below the industry average of 54.11% [3] - The gross profit margin was 10.88%, down from 11.99% year-on-year but still above the industry average of 9.94% [3] Group 3: Management and Shareholder Structure - The total compensation for General Manager Cheng Hui was 829,500, an increase of 229,500 from the previous year [4] - The largest shareholder is the Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. [4] Group 4: Shareholder Changes - As of September 30, 2025, the number of A-share shareholders decreased by 3.42% to 60,600 [5] - The average number of circulating A-shares held per household increased by 3.54% to 22,500 [5] Group 5: Future Outlook - According to Citic Securities, revenue is expected to grow by 4.00% year-on-year, while net profit is projected to decline by 27.20% [6] - The company is expected to achieve revenues of 16.79 billion, 17.47 billion, and 18.02 billion from 2025 to 2027, with net profits of 446 million, 723 million, and 928 million respectively [6] - Pacific Securities anticipates a net profit of 777 million and 1.315 billion for 2025 and 2026, respectively [6]